企業プロフィール
Pulmatrix 株価・ニュース・カタリスト
- ティッカー:
- PULM
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
1.56 USD (+1.30%)
終値
最終更新: 2026年8月17日
4.82M USD
時価総額
株価変動の要因
As of Aug 17, 2026, PULM closed up 1.30% at $1.56. No new same-company headline was identified in the current news window.
企業概要
Inhaled Drug-Delivery Company
Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology. The company is seeking partners or other monetization routes for its legacy clinical assets while pursuing a merger with Eos SENOLYTIX.
iSPERSE Technology
iSPERSE creates small, dense, dispersible particles intended to improve pulmonary drug delivery compared with conventional dry powders.
PUR1900
PUR1900 is an inhaled formulation of itraconazole for fungal lung disease. Partner Cipla controls continued development in India.
PUR3100 and PUR1800
PUR3100 is a Phase 2-ready inhaled dihydroergotamine program for acute migraine, while PUR1800 is an inhaled kinase inhibitor previously studied in chronic obstructive pulmonary disease.
今後のカタリスト
- Initiation of the Cipla-led Phase 3 study of PUR1900 in India in 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。